drugset / Trial / NCT01453504
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP
Timeline
- Start
- 2012-08
- Primary completion
- 2019-03
- Completion
- 2019-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Everolimus | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Cytarabine | Small molecule | — | — |
| Comparator | Dexamethasone | Small molecule | — | — |